Skip to main content

Table 1 Analysis of associations between clinicopathologic factors and effect of neoadjuvant chemotherapy

From: Predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer using multiparametric MRI

Variable All, n (%) pCR, n (%) Non-pCR, n (%) P value
Patient age (years) 48.7 ± 10.7 45.0 ± 10.4 49.9 ± 10.6 0.169
Tumor size (mm3)* 11.6 ± 11.2 11.7 ± 11.7 11.3 ± 10.1 0.936
Histological type*     
 Invasive 47 (94.0) 11 (91.7) 36 (94.7)  
 Other 3 (6.0) 1 (8.3) 2 (5.3) 0.696
Histologic grade*     
 1–2 34 (68.0) 11 (91.7) 23 (60.5)  
 3 16 (32.0) 1 (8.3) 15 (24.0) 0.060
Clinical stage*     
 II 18 (36.0) 9 (75.0) 9 (76.0)  
 III 32 (64.0) 3 (25.0) 29 (71.0) 0.001
T stage*     
 T1–T2 19 (38.0) 9 (75.0) 10 (26.3)  
 T3–T4 31 (62.0) 3 (25.0) 28 (73.7) 0.002
N stage*     
 N0 4 (8.0) 1 (8.3) 3 (7.9)  
 N1–3 46 (92.0) 11 (91.7) 35 (92.1) 0.961
Lymph node size*     
 ≤ 1.0 cm 29 (58.0) 7 (58.3) 22 (57.9)  
 > 1.0 cm 21 (42.0) 5 (41.7) 16 (42.1) 0.979
NAC regimen     
 EC 16 (32.0) 4 (33.3) 12 (31.6)  
 EC-T(H) 24 (48.0) 6 (50.0) 18 (47.4)  
 TEC or other 10 (20.0) 2 (16.7) 8 (21.1) 0.947
AC cycle     
 1–4 16 (32.0) 3 (25.0) 13 (34.2)  
 5–8 34 (68.0) 9 (75.0) 25 (65.8) 0.551
CEA level*     
 Normal 45 (90.0) 11 (91.7) 34 (89.5)  
 Abnormal 5 (10.0) 1 (8.3) 4 (10.5) 0.654
CA125 level*     
 Normal 46 (92.0) 11 (91.7) 35 (92.1)  
 Abnormal 4 (8.0) 1 (8.3) 3 (7.9) 0.961
CA153 level*     
 Normal 45 (90.0) 10 (83.3) 35 (92.1)  
 Abnormal 5 (10.0) 2 (16.7) 3 (7.9) 0.377
Breast cancer subtype     
 TNBC 12 (24.0) 4 (33.3) 8 (21.1)  
 Her-2 positive 10 (20.0) 2 (16.7) 8 (21.1)  
 Luminal A(B) 28 (56.0) 6 (50.0) 22 (57.9) 0.683
Ki-67 status     
 ≤ 20% 15 (30.0) 2 (16.7) 13 (34.2)  
 > 20% 35 (70.0) 10 (83.3) 25 (65.8) 0.248
  1. NAC neoadjuvant chemotherapy, TNBC triple-negative breast cancer, EC epirubicin plus cyclophosphamide, TH docetaxel plus Herceptin, TEC docetaxel, epirubicin plus cyclophosphamide
  2. *Data are measured at baseline. The data of patient age and tumor size are mean ± standard deviation